Transgenic overexpression of human Bcl-2 in islet beta cells inhibits apoptosis but does not prevent autoimmune destruction

Citation
J. Allison et al., Transgenic overexpression of human Bcl-2 in islet beta cells inhibits apoptosis but does not prevent autoimmune destruction, INT IMMUNOL, 12(1), 2000, pp. 9-17
Citations number
59
Categorie Soggetti
Immunology
Journal title
INTERNATIONAL IMMUNOLOGY
ISSN journal
09538178 → ACNP
Volume
12
Issue
1
Year of publication
2000
Pages
9 - 17
Database
ISI
SICI code
0953-8178(200001)12:1<9:TOOHBI>2.0.ZU;2-5
Abstract
Insulin-dependent diabetes mellitus results when > 90% of the insulin-produ cing beta cells in the pancreatic islets are killed as a result of autoimmu ne attack by T cells. During the progression to diabetes, islet beta cells die as a result of different insults from the immune system, Agents such as perforin and granzymes, CD95 ligand and tumor necrosis factor-alpha, or cy tokines and free-radicals have all been shown to cause beta cell apoptosis. The anti-apoptotic protein, Bcl-2, might protect against some of these sti muli. We have therefore generated transgenic mice expressing human Bcl-2 in their islet beta cells. Although Bcl-2 was able to prevent apoptosis induc ed by cytotoxic agents against beta cells in vitro, Bcl-2 alone could not p revent or ameliorate cytotoxic or autoimmune beta cell damage in vivo.